CytomX Therapeutics (CTMX) Common Equity (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Common Equity came in at $319.9 million in Q1 2026, up 1177.27% YoY from $25.0 million in Q1 2025, and up 223.15% on a QoQ basis from $99.0 million in Q4 2025.
CytomX Therapeutics (CTMX) Common Equity (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Common Equity data on file, last reported at $319.9 million in Q1 2026.
- Quarterly Common Equity rose 1177.27% year-over-year to $319.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $319.9 million (up 1177.27% YoY) and the FY2025 annual result came in at $99.0 million, up 21812.28% from the prior year.
- Common Equity improved to $319.9 million in Q1 2026, from $99.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $319.9 million in Q1 2026 to a low of -$86.6 million in Q1 2023.
- A 5-year average of $3.7 million and a median of -$31.2 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity tumbled 18582.14% — and 2025, when it jumped 21812.28%.
- Tracing CTMX's Common Equity over 5 years: stood at -$85.8 million in 2022, then jumped by 44.67% to -$47.4 million in 2023, then jumped by 99.04% to -$456000.0 in 2024, then jumped by 21812.28% to $99.0 million in 2025, then jumped by 223.15% to $319.9 million in 2026.
- The last three Common Equity figures came in at $319.9 million (Q1 2026), $99.0 million (Q4 2025), and $107.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 302.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 302.07 Mn |
| Mar 31, 2026 | 319.94 Mn |
| Dec 31, 2025 | 99.01 Mn |
| Sep 30, 2025 | 107.39 Mn |
| Jun 30, 2025 | 119.91 Mn |
| Mar 31, 2025 | 25.05 Mn |
| Dec 31, 2024 | -456,000.00 |
| Sep 30, 2024 | -23.45 Mn |
| Jun 30, 2024 | -31.23 Mn |
| Mar 31, 2024 | -31.68 Mn |
| Dec 31, 2023 | -47.45 Mn |
| Sep 30, 2023 | -51.24 Mn |
| Jun 30, 2023 | -85.03 Mn |
| Mar 31, 2023 | -86.64 Mn |
| Dec 31, 2022 | -85.75 Mn |
| Sep 30, 2022 | -80.54 Mn |
| Jun 30, 2022 | -54.54 Mn |
| Mar 31, 2022 | -29.74 Mn |
| Dec 31, 2021 | -459,000.00 |
| Sep 30, 2021 | 30.43 Mn |